Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).
查爾斯敦，馬薩諸塞州，2025年1月8日（環球新聞通訊社）-- Solid Biosciences Inc.（納斯達克：SLDB）（"公司"或"Solid"），一家爲神經肌肉和心臟疾病開發精準基因藥物的生命科學公司，今天宣佈總裁兼首席執行官Bo Cumbo將在2025年1月15日（星期三）下午3:45（太平洋時間）/ 下午6:45（東部時間）在第43屆J.P. 摩根醫療會議上進行演講。
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
演講的現場直播將在公司網站投資者部分的活動頁面上提供，或者點擊這裏。網絡直播回放將在活動頁面上存檔30天。
Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representatives.
有興趣在會議期間與管理層會面的機構投資者可以與他們的J.P.摩根代表聯繫。
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit .
關於Solid Biosciences
Solid Biosciences是一家專注於推進基因治療候選藥物組合的精準基因醫學公司，包括用於治療杜氏肌營養不良症（Duchenne）的SGt-003、用於治療弗里德里希共濟失調的SGt-212、用於治療兒茶酚胺多形性室性心動過速（CPVT）的SGt-501、用於治療TNNT2介導的擴張型心肌病的SGt-601、用於治療BAG3介導的擴張型心肌病的SGt-401，以及用於治療致命性心臟疾病的其他資產。Solid正在推進其在罕見神經肌肉和心臟疾病方面的多樣化管線，彙集了科學、技術、疾病管理和護理的專家。以患者爲中心，由那些直接受影響的人創立，Solid的任務是改善生活在這些毀滅性疾病中的患者的日常生活。有關更多信息，請訪問。
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Solid Biosciences 投資者聯繫：
妮可·安德森
董事，投資者關係與企業通信
Solid Biosciences 公司
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
媒體聯繫人：
格倫·白銀
FINN Partners
glenn.silver@finnpartners.com
譯文內容由第三人軟體翻譯。
